Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. - Wikidata - awgldk - TriplyDB

Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

http://www.wikidata.org/entity/Q33828114

about

Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells.Gene therapy from the perspective of systems biology.DCVax®-L--developed by Northwest Biotherapeutics Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.Single vs. combination immunotherapeutic strategies for glioma.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics Gene transfer into rat brain using adenoviral vectors.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.The value of EGFRvIII as the target for glioma vaccines.Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Pro-apoptotic effects of rHSG on C6 glioma cells.Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.The art of gene therapy for glioma: a review of the challenging road to the bedside Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy.Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.Canine brain tumours: a model for the human disease?Antitumor activity of combined endostatin and thymidine kinase gene therapy in C6 glioma models.Convection-enhanced Delivery of Therapeutics for Malignant Gliomas.Evaluation of resveratrol sensitivities and metabolic patterns in human and rat glioblastoma cells.Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma.Targeted Gene Therapy of Cancer: Second Amendment toward Holistic Therapy.Immunomodulatory effects of hemagglutinin- (HA-) modified A20 B-cell lymphoma expanded as a brain tumor on adoptively transferred HA-Specific CD4+ T cells.Gene therapy and targeted toxins for glioma

P2860

Q30010026-300BBCC5-C72A-446E-8706-76528F6D283E Q30430438-F91B8304-CCE0-44F0-88FF-E10927721A62 Q30875456-EF6E07E3-49CD-4787-964F-E1A1EFD73571 Q33605719-553F8DD9-A2A7-4CD5-B7A0-5A2BECEB57EC Q33746041-32692F69-FBA1-45AB-A290-765150AF7AA3 Q33877450-3BB51A67-3F5F-4911-9470-F454DE7E6BD3 Q33904294-181A9D7C-C3C9-41AF-BFA0-24D9D1E54146 Q34012284-42E818E4-3E38-484A-BF0A-BDDAE3FC4769 Q35285859-011C52CD-6E37-4200-8297-0D20C64128AD Q35627573-DA9CD8EB-E084-416D-9020-B4BFF4183803 Q35999648-AFA0437F-03A3-4972-BCF7-B41F3D033A91 Q36124303-D373B075-518C-47F5-93D6-DC66B86F17C1 Q36200438-F2C36589-A115-45BD-8C99-61C1227F1311 Q36527593-B5537E00-393F-48C1-8AD6-E59203CEA318 Q36811505-4D58F898-C809-4691-9ADB-8F64DDE6E52E Q37804933-8E8E5378-28C4-4882-A6E5-A0DC35C01311 Q37965751-A5BB26D5-194C-4084-9DB9-D421BE4F4CF3 Q37989984-40F5E360-47D7-45FB-BB62-550FDDA5C69E Q38063945-063AFD22-6AC7-483D-A38F-041937C31CA3 Q38107203-E6218DDA-D1EB-4C30-BA4E-906DB93BB1E8 Q38491009-B4BD7B2E-4FC3-4FBD-98DA-EBAB2A97CD19 Q38760482-B9B7608C-8492-4A05-AD6F-5281B7025C4C Q38782309-07CD356D-66B7-4AB7-809D-D4C9448F9FD5 Q39103076-0250EF07-4FDA-4E17-BFE5-7FE093872839 Q39210624-2CBE5ACC-7E0C-4849-91F7-FA7DF45423D0 Q39356646-C6B4F4C6-F87A-418E-95FA-AD00E3850903 Q41901950-0725C3EC-94BA-41A5-8141-60558D47FF9A Q53584094-7C66F51E-0393-46B0-A4F9-83CC269054A7 Q57006162-BDCF655A-75B0-4BBF-AB53-82E62A41CF36

P2860

Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

http://www.wikidata.org/entity/Q33828114

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Gene therapy for brain cancer: ...... enhanced efficacy and safety.

@ast

Gene therapy for brain cancer: ...... enhanced efficacy and safety.

@en

type

label

Gene therapy for brain cancer: ...... enhanced efficacy and safety.

@ast

Gene therapy for brain cancer: ...... enhanced efficacy and safety.

@en

prefLabel

Gene therapy for brain cancer: ...... enhanced efficacy and safety.

@ast

Gene therapy for brain cancer: ...... enhanced efficacy and safety.

@en

P1433

Q33828114-EB67F3D6-1F8B-454B-BEA7-78E56B6D7CDB

P1476

Q33828114-F75CA2D7-613D-4CB6-BC01-20F737325222

P2093

Q33828114-077C65C6-EE37-436D-8C54-118F9EE74658

Q33828114-62A7931A-57BB-4236-8BAC-375ABC996075

Q33828114-7FB23580-3DBB-4BA9-833B-CC580FAFF1E9

Q33828114-A4120B30-AD8E-4361-9FC1-4C1E5CC1B098

Q33828114-B0D7ECB8-B3BA-4BCF-B6A5-1A88B5815B3A

Q33828114-CD590E64-8FA5-4866-9154-9B59A6E1FD8B

Q33828114-D95CA190-7483-4B7C-AD0E-0BCD593DB616

P2860

Q33828114-00D5DF39-CD80-4C0E-AFB3-8873611AFEF9

Q33828114-046034A7-1CC8-449D-B915-016FED8A097A

Q33828114-06E142D6-15CC-430A-ACCA-CE8FAA9B6A20

Q33828114-07D094B1-7308-4CF1-9A64-248925255344

Q33828114-08DB14E5-20D1-4A9E-B635-1C0E9F067A52

Q33828114-091552E4-5982-47F9-94A3-DCDF6E3BC549

Q33828114-0D795CE6-2F7B-4DE6-B6F9-FFAFB06FDE23

Q33828114-0DFE7E61-65C4-46D9-8333-EA89927E8F87

Q33828114-0FC56F10-01FE-4EF0-87BC-411C96F4138D

Q33828114-107C17B0-22BC-41AA-A319-392EB8E2F998

P304

Q33828114-6C984713-C00E-4DB9-8F4F-7A72261149CB

P31

Q33828114-E6C6E3E4-9754-4B25-A549-CF3BCCEA2358

P356

Q33828114-D9772F42-FD41-4DA3-9D44-7A3B3A592CAA

P407

Q33828114-AD4D16C8-B105-4221-A48C-FE0FCBF8CB10

P433

Q33828114-27B2C412-A811-4934-AF16-DCECFDC9D80E

P478

Q33828114-796C0330-2570-4428-9F83-0D146B2B4798

P50

Q33828114-5DBD944B-6224-466B-8A5C-FDC6E535B8C5

P577

Q33828114-77549EE3-11E7-499B-B2A8-B87BE66C5C49

P698

Q33828114-684564E6-C6FB-4CF1-BF18-A684AD05E38C

P921

Q33828114-5459A445-6FB6-4270-81BF-AD5FD5220344

P932

Q33828114-8DA67DBC-780C-4568-8E76-05A26662601B

P356

156652309789753301

P1433

Current Gene Therapy

P1476

Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety

@en

P2093

A K M G Muhammad

http://www.w3.org/2001/XMLSchema#string

Catherine Farrokhi

http://www.w3.org/2001/XMLSchema#string

Kader Yagiz

http://www.w3.org/2001/XMLSchema#string

Kurt M Kroeger

http://www.w3.org/2001/XMLSchema#string

Marianela Candolfi

http://www.w3.org/2001/XMLSchema#string

Pedro R Lowenstein

http://www.w3.org/2001/XMLSchema#string

Robert N Pechnick

http://www.w3.org/2001/XMLSchema#string

P2860

HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter

Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

Calreticulin exposure dictates the immunogenicity of cancer cell death

Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation

Malignant gliomas in adults

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

P304

409-421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/156652309789753301

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19860655

http://www.w3.org/2001/XMLSchema#string

P921

P932

2864138

http://www.w3.org/2001/XMLSchema#string